Neurogenesis during embryonic and adult life is tightly regulated by a network of transcriptional, growth and hormonal factors. Emerging evidence indicates that activation of the stress response, via the associated glucocorticoid increase, reduces neurogenesis and contributes to the development of adult diseases.As corticotrophin-releasing hormone (CRH) or factor is the major mediator of adaptive response to stressors, we sought to investigate its involvement in this process. Accordingly, we found that CRH could reverse the damaging effects of glucocorticoid on neural stem/progenitor cells (NS/PCs), while its genetic deficiency results in compromised proliferation and enhanced apoptosis during neurogenesis. Analyses in fetal and adult mouse brain revealed significant expression of CRH receptors in proliferating neuronal progenitors. Furthermore, by using primary cultures of NS/PCs, we characterized the molecular mechanisms and identified CRH receptor-1 as the receptor mediating the neuroprotective effects of CRH. Finally, we demonstrate the expression of CRH receptors in human fetal brain from early gestational age, in areas of active neuronal proliferation. These observations raise the intriguing possibility for CRH-mediated pharmacological applications in diseases characterized by altered neuronal homeostasis, including depression, dementia, neurodegenerative diseases, brain traumas and obesity.
INTRODUCTION
Living organisms maintain their physiological homeostasis during development as well as in adult life against constant challenges by internal and environmental stimuli. Although differentiated cells account for the majority of homeostatic functions, stem cells contribute critically to the whole process either by generation of differentiated cells or by changing their own function to adapt to the altered tissue/organ demands. 1 Thus, in a number of tissues, including the nervous system, tissue-specific stem cells persist throughout life and give rise to new cells in order to meet the demands of turnover and injury-induced cell loss. Along these lines, emerging evidence has linked changes in adult neurogenesis to the pathogenesis, and often to the success of therapeutic regimens, of major diseases such as depression. [2] [3] [4] [5] [6] Neurogenesis occurs constitutively in the embryonic brain and, as has been confirmed lately, to a lesser extent in specific niches of the adult brain. 7, 8 In the adult human and rodent brains, proliferation of neural stem/progenitor cells (NS/PCs) persists throughout life in areas such as the subventricular zones (SVZs) and the subgranular hippocampal zones. 8 Neurogenesis involves a tightly controlled process of spatiotemporal neuronal proliferation and programmed cell death 9 achieved by the orchestrated action of a network of transcription and growth factors. Additional intrinsic factors, such as secreted molecules, and environmental stimuli impact significantly on the potential of NS/PCs for proliferation, differentiation and survival, with mechanisms we start to understand better. [10] [11] [12] [13] [14] For example, excess levels of circulating glucocorticoid, such as during prolonged, unopposed stress, are associated with suppressed proliferation 12 and decreased survival of NS/PCs in the hippocampus. 15, 16 The adaptive response to challenges, otherwise stress or 'fightor-flight'response, 17 is a well-preserved process intimately associated with survival and development. In mammals, it is driven by the activation of the hypothalamic-pituitary-adrenal axis and the catecholaminergic system. 18 The critical step in the development of the stress response is the activation of the neuropeptide corticotropin-releasing hormone (CRH) or factor. 19 This response is self-limited as return back to homeostasis is linked to decrease in CRH neurons activation back to their basal state. 20 CRH is expressed early in the developing mouse brain, such as on E13.5 in forebrain and on E10 in the cerebellum 21, 22 correlating temporally with the birth of the first neurons from the neural progenitor cells of the ventricular layer. 22 In addition, in both the developing and the adult brain, CRH is expressed in the neurogenic niche of the hippocampal granular zone, a wellcharacterized neurogenic area. 21, 23 In the central nervous system, CRH has been shown to function as a neurotransmitter/ neuromodulator. 24 The first indication that CRH may be implicated in processes related to neuronal development and/or differentiation derived from the altered expression of genes involved in myelination and cell proliferation in transgenic mice overexpressing CRH. 25 CRH has been also implicated in the differentiation of noradrenergic neurons in the locus coeruleus during brain development. 26 CRH acts via binding to CRH receptor-1 (CRH-R1) and -2 (CRH-R2), members of the G-proteincoupled receptors (GPCRs) family. 27 Several GPCRs have been implicated in neurogenesis and apoptosis in site-and/or developmental stage-restricted manners. 28 In line, neuroprotective effects of CRH have been described during development, 23 in primary neuronal cultures exposed to toxic factors, 20 or in vivo following oxidative stress. 29, 30 Here, we present evidence that CRH regulates neurogenesis, an effect that could be considered as part of the adaptive response of the nervous system to various challenges. This regulatory role of CRH is in line with late reports on the contribution of CRH in the maintenance of peripheral tissue homeostasis following metabolic 31 or inflammatory stimuli. 32 In particular, we show that CRH through its receptor-1 (CRH-R1) is implicated in the control of proliferation and apoptosis of NS/PCs both in vitro and in vivo. Most importantly, CRH seems sufficient to reverse the glucocorticoidmediated suppression of proliferation and the associated induction of apoptosis in NS/PCs. Finally, we demonstrate the expression of CRH receptor(s) in the neurogenic areas of mouse and human brain. These data indicate a novel role of CRH and renders CRH as a potential therapeutic target for central nervous system-associated neurological disorders and diseases.
MATERIALS AND METHODS

Human tissues
Human embryos from 13 weeks old (n ¼ 4) were obtained from Alexandra Hospital and from Medical School, University of Athens, Greece. The ethics committees of the participating university and hospital approved tissue collection. Handling of tissue was carried out in accordance with all regulations of the institutional ethics committees.
Animals
Animals housing and care were according to NIH and EU guidelines. The Crh À / À mouse line was generated as described previously. 33 Crh-/-mice were raised in C57/Bl6 background and were obtained by crossing of heterozygous, their wildtype littermates, Crh þ / þ were used as controls.
Cell culture, fluorescence-activated cell sorting analysis, immunohistochemistry, BrdU, TUNEL assays, reverse transcriptase PCRs and western blotting Detailed methodology for all these assays is described in Supplementary Materials and Methods. [34] [35] [36] 
Statistical analysis
Results are expressed as mean±s.e.m. Data were analyzed by two-tailed, unpaired, equal variance Student t-test and defined as Po0.05.
For details of animals, cell culture, tissues processing, imaging and quantification, immunohistochemistry, 5-bromo-2-deoxyuridine (BrdU) and terminal transferase dUTP nick-end labeling (TUNEL) assays, PCR analysis and statistical analysis, see Supplementary Materials and Methods.
RESULTS
Evidence for altered neurogenesis in the CRH-deficient mice To assess the impact of CRH in mouse neurogenesis, we used the Crh-null (Crh À / À ) mouse with global CRH deficiency, and the corresponding glucocorticoid insufficiency. 33 We used heterozygote pregnancies taking advantage of the fact that in that case all embryos, independent of their genotype, are exposed to similar glucocorticoid levels of maternal origin. Proliferation was assessed by immunohistochemistry of multiple tissue sections following BrdU administration on E14.5 for 2 h. As shown, significantly fewer BrdU-positive NS/PCs were identified in the proliferating layers of the cerebral cortex of Crh À / À mice compared with their littermate wild-type mice (Figures 1a and c) . CRH blocks glucocorticoid toxicity in NS/PCs and exerts glucocorticoid-independent neuroprotective effects Glucocorticoid is one of the hormonal factors mostly studied as a negative regulator of neurogenesis via direct pro-apoptotic and, to a lesser extent, anti-proliferative effects on NS/PCs. 38 Glucocorticoid release in dependent on CRH activation, an effect severely compromised in Crh À and Crhr1 À null mice 33, 39 To evaluate the possibility that CRH is involved in the effects of glucocorticoid on NS/PCs, we studied first the proliferation of glucocorticoidexposed NS/PCs, as revealed by BrdU incorporation. Treatment of NS/PCs with the synthetic glucocorticoid dexamethasone as expected reduced their proliferation by 50%, while co-treatment with CRH (10 À 7 M) for 24 h abolished the suppressive effect of glucocorticoid (Figures 3a and b) . Interestingly, treatment with CRH alone increased the abundance of BrdU-positive NS/PCs, by B30% as compared with vehicle treatment (Figures 3a and b) . It should be mentioned that according to a recent study, the concentration of CRH in hippocampus can reach 200 nM during stress. 23, 40 Next, we evaluated the impact of co-treatment with CRH on the glucocorticoid-induced NS/PCs' apoptosis by TUNEL assay. As shown, CRH was sufficient to protect NS/PC from dexamethasone-induced apoptosis (Figures 3c and d) . Taken together, these results suggest that CRH exerts direct, glucocorticoid-independent effects on mouse NS/PCs. Furthermore, CRH may counteract the negative effect of glucocorticoid on proliferation and survival of NS/PCs by its direct neuroprotective actions.
CRH stimulates NS/PCs proliferation and blocks apoptosis via CRH-R1 receptor To determine which CRH receptor(s) mediate the effects of CRH on NS/PCs, we employed specific antagonists, a very good tool available, especially given the limited specificity of the commercially available antibodies for each specific CRH receptor subtype. We applied the non-peptide CRH-R1 antagonist, antalarmin, or the CRH-R2 antagonist, astressin 2b, 30 min before CRH treatment. When CRH was administrated together with astressin 2b, the total number of BrdU-positive cells was not affected compared with CRH-treated cells alone (Figures 4a-c) . In contrast, when CRH was administered in the presence of the antalarmin, the proliferative effects of CRH were abolished (Figures 4a-c) , suggesting a CRH-R1-specific effect. Next, we evaluated the effects of the two antagonists on the CRH-induced protection of NS/PCs from apoptosis. As shown by TUNEL assay, it was antalarmin only that reversed the effect of CRH. These findings demonstrate the specificity of the above effects of CRH on NS/PCs mediated by CRH-R1 alone (Figures 4b-d) .
To further elucidate the molecular mechanisms mediating the aforementioned effects of CRH and their relevance in human cells, we used the human neuroblastoma cell line, SH-SY5Y. 41 Similar to the effects on NS/PCs, CRH induced proliferation of SH-SY5Y cells, whereas analysis of the cell cycle profiles by fluorescenceactivated cell sorting showed a higher percentage of cells in the S phase (Supplementary Figure S1A ) and significant induction of the expression of cyclin D1 (Supplementary Figure S1B) . Serum deprivation followed by TUNEL assay showed reduction of apoptotic bodies by B50%, and increased expression of caspase-3 (Supplementary Figure S1C) following CRH treatment. The above data support our findings in NS/PCs and indicate cyclin D1 and caspase-3 as significant factors in the CRH-mediated neuroprotection.
Distinct signaling pathways mediate the effects of CRH/CRH-R1 on NS/PCs Binding of CRH to CRH-R1 induces the activation of cAMP and, in several cells and tissues, it is shown to engage additional signaling pathways, including mitogen-activated protein kinase (MAPK) and PI3K/Akt. 20, 38 To elucidate the contribution of these pathways in the neuroprotective effects of CRH, we applied specific inhibitors. As shown, PD98059, a MAPK inhibitor, blocked the CRH-induced increase of BrdU-positive NS/PCs, while co-treatment with wortmanin, that blocks activation of the PI3 kinase, had no effect (Figures 4a and c) . In contrast, wortmanin blocked the antiapoptotic effect of CRH, whereas no effect of PD98059 was detected (Figures 4b and d ). These findings demonstrate that two distinct intracellular signaling pathways, MAPK and PI3K/Akt, are specifically involved in the proliferative and anti-apoptotic effects of CRH/CRH-R1 on NS/PCs.
Expression of CRH receptors in proliferating zones of the developing human brain To assess the potential implications of our findings in humans, we assessed the expression of CRH receptors in the developing human brain. We performed immunostainings with specific antibody that recognizes both CRH receptors (CRHRs). As shown, we detected wide expression of CRHRs in the fetal human brain from 13 weeks embryo (Figure 5a ). Most importantly, there were high levels of expression staining in the ventricular and SVZ (Figures 5b-b 0 ), both rich in proliferating cells as revealed by staining for Ki67 (Figure 5c ). Our findings demonstrate for the first time CRH receptors in the human brain in the proliferating neuronal cells from early fetal age and provide evidence for the possible relevance of our findings in human neurogenesis.
DISCUSSION
In this study, we demonstrate that CRH, identified as the major mediator of the stress response and glucocorticoid release in mammals, exerts protective effects on mouse neural progenitors/ stem cells. We show that CRH receptors are expressed in neurogenic areas of fetal and adult mouse brain and that CRH-R1 mediates the above effects of CRH, via activation of distinct signaling pathways, MAPK and PI3K. We also provide evidence that CRH can oppose the neurotoxic effects of excess glucocorticoid on neuronal progenitors. Finally, we demonstrate that CRHRs are expressed in the dividing human fetal brain cells.
We found compromised neuronal proliferation and increased rates of apoptosis in the Crh À / À fetal mouse brain as compared with wild-type tissue (Figure 1 ). CRH receptors are broadly expressed in the developing mouse neuroepithelium, particularly in actively proliferating, nestin-positive NS/PCs (Figure 2) , around the time window that neurogenesis occurs. Significant expression of CRH receptors in neurogenic niches persisted in adult brain, with the strongest staining in the SVZ/rostral migratory stream. This area is considered critical for recovery from ischemia, generation of GABAergic neurons and olfaction. 41, 42 As shown (Figure 2) , a good proportion of all distinct cell types in the lineage of adult neurogenesis, including GFAP þ , Nestin þ , Mash1 þ and DCX þ cells, were also positive for CRHRs staining. The high abundance of CRH receptors in the mouse cortical neurogenic areas (Figure 2 ) and the altered cell proliferation and apoptosis in the same areas of the Crh À / À brain (Figure 1) suggested the possibility that CRH may have direct effects on NS/PCs. Indeed, culture of NS/PCs in the presence of CRH resulted in dramatic enhancement, by B60%, of the proportion of proliferating cells (Figures 3 and 4) . It seems that CRH exerts a dual effect on NS/PCs, by increasing the proportion of cells that will remain in the proliferating state and enhancing their ability to overcome apoptosis (Figure 4) . Although by reverse transcriptase PCR both CRH receptors are expressed in NS/PCs, it appears that the neuroprotective effects of CRH on these cells are mediated by CRH-R1, as they were completely abolished by co-treatment with antalarmin, a CRH-R1-specific antagonist (Figure 4) . Recent studies report different effects of CRH acting via CRH-R1 on proliferation and survival of cells from a variety of origins. Thus, both inhibition of the proliferation of epidermal keratinocytes, 43, 44 human breast cancer and endometrial adenocarcinoma cells, 45 and stimulation of the proliferation of b-cells in the pancreas 31 were shown. In our hands, CRH induced proliferation and protected from apoptosis the human neuroblastoma SH-SY5Y cells, that express CRHRs and have been used to study neuroprotection (Supplementary Figure  S1) . Several reasons may account for the discrepancies between the reported effects of the CRH/CRH-R1 on cell proliferation, such as tissue-specific factors, co-expression of CRH-R2 and/or additional ligands, the cell type, that is, primary versus stable cell line.
Neural mitogenic signaling has been primarily associated with the activation of tyrosine kinase receptors, [46] [47] [48] whereas emerging evidence points to similar effects following activation of several GPCRs. 49, 50 CRH receptors belong to the class B subfamily of GPCRs that in addition to cAMP activation, in several tissues or cells, act through induction of NFkB, MAPK and PI3K. [51] [52] [53] Modulation of neuronal survival analogous to that we found for CRH has been described for PACAP, VIP and MIP-2 54,55 ligands of other GPCRs. Our present data suggest that the dual effects, mitogenic and anti-apoptotic, of CRH on neural progenitor populations are specific and achieved via distinct signal transduction pathways, MAPK and PI3K, respectively (Figure 4) . These findings were replicated in the SH-SY5Y cells, that provided a tool to show specific effects of CRH in cell cycle events and induction of cyclin D1 (Supplementary Figure S1) . A similar mechanism has been postulated for the neuroprotective effects of VEGF. 56 Using the same system, we found inhibition of the activation of caspase-3 by CRH (Supplementary Figure S1) , similar to previous reports on VIP and PACAP. 54 Neuroprotective effects of CRH/CRH-R1 have been described in primary and permanent cell lines as well as in cultured brain slices, 20 following exposure to neurotoxic agents such as amyloid, 30 glutamate and lipid peroxides or hypoxia. 57, 58 On the other side, there is a body of reports on the hazardous effects of CRH/CRHR1 in the brain in association with chronic stress and the corresponding increase in glucocorticoid. 59 Glucocorticoid receptors are expressed in the developing neuroepithelium, and the proliferation of NS/PCs has been decreased dramatically following dexamethasone or corticosterone treatment. 60, 61 Furthermore, high levels of glucocorticoid has been considered as the major cause of the stress-induced neuronal death, 60, 62 evidenced, for example, by reduction of the volume of the dentate gyrus during chronic stress. 63 Here, we demonstrate blockade of these effects of glucocorticoid following co-treatment with CRH ( Figure 3) . Based on the above, it is possible that CRH and glucocorticoid have exerted opposing effects on the proliferation of NS/PCs. Along these lines, it was recently shown glucocorticoid inhibit cyclin D1, 60, 61 an effect opposite to our current findings with CRH. To our knowledge, this is the first study that demonstrates specific effects of CRH on physiological neurogenesis and the mechanisms involved. In agreement with our results, it has been shown that connexin 43, a factor expressed in fetal brain and involved in neurogenesis, mediates the neuroprotective effects of CRH. 64 It is in support of the intriguing possibility of the applicability of our findings in human neurogenesis, the identification of CRHR in human fetal dividing neurons ( Figure 5 ). Furthermore, detailed analysis of the expression of the CRHR1 and CRHR2 genes in human tissues showed expression for both in the hippocampus to levels similar or even higher than in the amygdala, one of the main areas for CRH action. 65 In a recent study, looking at the effect of CRH specifically in hippocampal pyramidal cells, the authors suggested that physiological release of low levels of CRH seem to be required for normal function of differentiated neurons. 40 In summary, our findings demonstrate stimulatory effects of CRH on mouse neurogenesis and indicate a direct homeostatic role for CRH in antagonizing the negative effects of glucocorticoid in neuronal survival. Our working hypothesis is that CRH exerts direct, beneficial effects on neuronal progenitors, via its specific receptor CRH-R1. These effects are unmasked in states of severe stress owing to the prolonged and significant rise in glucocorticoid and the associated inhibition of CRH expression. 66 More studies are needed to provide further insights on the role of this peptide in human neuronal stem and progenitor cells. Our study raises the possibility for potential therapeutic application of CRH/CRHR1 in the treatment of brain and neurodegenerative disorders by support of specific neuronal actions. 
